InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression.

Biotechnology

InterVenn Biosciences

Joshua Stahl

Jonathan Hirokawa

Peter S.

Andrew Quong

Kim MacMartin-Moglia

Ada Wong

Kaitlynn Moser

Dan Serie

Clinical Development & Research

Leadership Team

Medical Advisory Team

Advisory Team

Business Development and Marketing

Data Engineering Team